CP 461 free base
CP 461 free base (OSI-461 free base) is a novel pro-apoptotic compound with the activity of inhibiting cyclic guanosine monophosphate phosphodiesterase. CP 461 free base exhibits growth inhibitory activity against a variety of human tumor cell lines in vitro. CP 461 free base selectively induces apoptosis in cancer cell lines but has no effect on normal cells. CP 461 free base can be used in the study of renal cell carcinoma, prostate cancer and Crohn's disease.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 227619-92-3
- Formule: C25H21FN2O
- Masse moléculaire:384.45
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HT-29 | CC50 |
2.14 μM
Compound: 86
|
Growth inhibition of human HT-29 cells after 72 hrs by CellTiter-Glo reagent based assay
Growth inhibition of human HT-29 cells after 72 hrs by CellTiter-Glo reagent based assay
|
[PMID: 28935266] |
| MDA-MB-231 | CC50 |
3.68 μM
Compound: 86
|
Growth inhibition of human MDA-MB-231 cells after 72 hrs by CellTiter-Glo reagent based assay
Growth inhibition of human MDA-MB-231 cells after 72 hrs by CellTiter-Glo reagent based assay
|
[PMID: 28935266] |
| PC-3 | CC50 |
5.71 μM
Compound: 86
|
Growth inhibition of human PC3 cells after 72 hrs by CellTiter-Glo reagent based assay
Growth inhibition of human PC3 cells after 72 hrs by CellTiter-Glo reagent based assay
|
[PMID: 28935266] |
Chemical Information
-
CAS No. 227619-92-3
-
Masse moléculaire 384.45
-
Formule C25H21FN2O
-
SMILES
O=C(NCC1=CC=CC=C1)CC(C2=CC(F)=CC=C2/3)=C(C)C3=C\C4=CC=NC=C4
-
Synonyms
OSI-461 free base
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)